Section 505 of the Food, Drug, and
Cosmetic Act requires that a new drug may not be marketed unless
the manufacture provides FDA with scientific evidence that the drug
is both safe and effective. The regulations at 21 CFR Part 314
provide the means through which pharmaceutical manufacturers can
obtain FDA approval of a drug product marketing application, and
the means through which FDA can assure the safety and effectiveness
of the marketed products.
OMB requested 0910-0528 to be
merged with 0910-0001.
$0
No
No
Uncollected
Uncollected
Uncollected
Uncollected
Howard Muller 301 594-2041
howard.mullerjr@fda.hhs.gov
No
On behalf of this Federal agency, I certify that
the collection of information encompassed by this request complies
with 5 CFR 1320.9 and the related provisions of 5 CFR
1320.8(b)(3).
The following is a summary of the topics, regarding
the proposed collection of information, that the certification
covers:
(i) Why the information is being collected;
(ii) Use of information;
(iii) Burden estimate;
(iv) Nature of response (voluntary, required for a
benefit, or mandatory);
(v) Nature and extent of confidentiality; and
(vi) Need to display currently valid OMB control
number;
If you are unable to certify compliance with any of
these provisions, identify the item by leaving the box unchecked
and explain the reason in the Supporting Statement.